Evan Hersh

Evan Hersh

UNVERIFIED PROFILE

Are you Evan Hersh?   Register this Author

Register author
Evan Hersh

Evan Hersh

Publications by authors named "Evan Hersh"

Are you Evan Hersh?   Register this Author

29Publications

535Reads

50Profile Views

Attack of the clones: reproductive interference between sexuals and asexuals in the agamic complex.

Ecol Evol 2016 09 18;6(18):6473-6483. Epub 2016 Aug 18.

Department of Botany and Biodiversity Research Centre The University of British Columbia 6270 University Boulevard Vancouver British Columbia Canada V6T 1Z4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ece3.2353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058521PMC
September 2016

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

Clin Med Insights Oncol 2012 30;6:275-86. Epub 2012 Jul 30.

Department of Medicine, Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S7245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418148PMC
August 2012

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

Invest New Drugs 2010 Oct 6;28(5):634-40. Epub 2009 Jun 6.

Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Unit 1354, 1155 Pressler Street, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9273-1DOI Listing
October 2010

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.

Cancer 2010 Aug;116(15):3683-91

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25119DOI Listing
August 2010

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.

Cancer Chemother Pharmacol 2010 Jul 24;66(2):287-94. Epub 2009 Oct 24.

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C307, Philadelphia, PA 19111-2497, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1162-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873145PMC
July 2010

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

J Clin Oncol 2009 Dec 16;27(36):6207-12. Epub 2009 Nov 16.

Melanoma Program, The Angeles Clinic and Research Institute, 2001 Santa Monica Blvd, Suite 560 W, Santa Monica, CA 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.20.3075DOI Listing
December 2009

Phase I/II study of ipilimumab for patients with metastatic melanoma.

J Clin Oncol 2008 Dec 17;26(36):5950-6. Epub 2008 Nov 17.

University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.1927DOI Listing
December 2008

The role of the CTLA4 blockade in the treatment of malignant melanoma.

Cancer Invest 2007 Oct;25(7):613-31

Melanoma/Sarcoma Program, Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900701522315DOI Listing
October 2007

Phase I trial of imexon in patients with advanced malignancy.

J Clin Oncol 2007 May;25(13):1779-84

College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.08.9672DOI Listing
May 2007

Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.

Anticancer Drugs 2006 Nov;17(10):1179-84

Arizona Cancer Center, Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000236305.43209.f0DOI Listing
November 2006

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

J Clin Oncol 2005 Nov;23(31):7785-93

Department of Pharmacology Toxicology, Division of Hematology/Oncology, Arizona Cancer Center/University of Arizona Health Sciences Center, Tucson, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.00.6148DOI Listing
November 2005

Rodent models of brain metastasis in melanoma.

Melanoma Res 2005 Oct;15(5):325-56

Section of Hematology and Oncology, The Arizona Cancer Center, University of Arizona/University Medical Center, Tucson, Arizona 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00008390-200510000-00002DOI Listing
October 2005

Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.

Cancer Immunol Immunother 2004 Aug 26;53(8):705-14. Epub 2004 Mar 26.

Arizona Cancer Center, 1515 N. Campbell Avenue, PO Box 245024, Tucson 85748, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-004-0512-1DOI Listing
August 2004

Clinical applications of dendritic cell vaccination in the treatment of cancer.

Cancer Immunol Immunother 2004 Apr 26;53(4):275-306. Epub 2003 Nov 26.

Department of Hematology and Oncology, The Arizona Cancer Center, University of Arizona/University Medical Center, 1515 N. Campbell Ave., Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-003-0432-5DOI Listing
April 2004

Naturally occurring B-cell responses to breast cancer.

Cancer Immunol Immunother 2003 Dec 15;52(12):715-38. Epub 2003 Aug 15.

Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-003-0409-4DOI Listing
December 2003

Feasibility to generate monocyte-derived dendritic cell from coculture with melanoma tumor cells in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-4.

Am J Reprod Immunol 2003 Apr;49(4):230-8

Department of Obstetrics and Gynecology, BK21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0897.2003.01200.xDOI Listing
April 2003